PMID- 24675508
OWN - NLM
STAT- MEDLINE
DCOM- 20140516
LR  - 20171213
IS  - 2038-2529 (Electronic)
IS  - 0300-8916 (Linking)
VI  - 100
IP  - 1
DP  - 2014 Jan-Feb
TI  - Everolimus in advanced solid tumors: when to start, early or late?
PG  - e2-3
LID - 10.1700/1430.15827 [doi]
AB  - Everolimus is an oral derivative of rapamycin which acts as a signal transduction 
      inhibitor. It targets the mammalian target of rapamycin (mTOR), a key 
      serine/threonine kinase regulating cell growth and angiogenesis. Everolimus has 
      been approved for the treatment of pancreatic neuroendocrine tumors (pNETs), 
      metastatic renal cell carcinoma (mRCC), and breast carcinoma. The activity of 
      everolimus was demonstrated in three phase III randomized placebo-controlled 
      trials, RADIANT-3, RECORD 1 and BOLERO 2, in patients with pNETs, mRCC and breast 
      carcinoma, respectively. All three trials reported a statistically significant 
      increase in median progression-free survival, the primary endpoint of the 
      studies, in favor of everolimus. The absence of an overall survival benefit could 
      be related to the cross-over design and subsequent therapies. The focus of our 
      paper is on the best timing to start treatment with everolimus, while additional 
      questions concern the opportuneness of intermittent use of everolimus 
      specifically in long-responding patients. Lastly, we suggest this treatment could 
      be optimized on the basis of patient and disease characteristics.
FAU - Pusceddu, Sara
AU  - Pusceddu S
FAU - Tessari, Anna
AU  - Tessari A
FAU - Testa, Isabella
AU  - Testa I
FAU - Procopio, Giuseppe
AU  - Procopio G
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumori
JT  - Tumori
JID - 0111356
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Disease Progression
MH  - Drug Administration Schedule
MH  - Everolimus
MH  - Humans
MH  - Neoplasms/*drug therapy/pathology
MH  - Randomized Controlled Trials as Topic
MH  - Sirolimus/administration & dosage/*analogs & derivatives
MH  - Treatment Outcome
EDAT- 2014/03/29 06:00
MHDA- 2014/05/17 06:00
CRDT- 2014/03/29 06:00
PHST- 2014/03/29 06:00 [entrez]
PHST- 2014/03/29 06:00 [pubmed]
PHST- 2014/05/17 06:00 [medline]
AID - 10.1700/1430.15827 [doi]
PST - ppublish
SO  - Tumori. 2014 Jan-Feb;100(1):e2-3. doi: 10.1700/1430.15827.